ECM
EagleClaw Capital Management’s Charles River Laboratories CRL Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-15,705
| Closed | -$3.24M | – | 140 |
|
|
2024
Q2 | $3.24M | Sell |
15,705
-100
| -0.6% | -$20.7K | 0.58% | 49 |
|
|
2024
Q1 | $4.28M | Sell |
15,805
-310
| -2% | -$84K | 0.78% | 44 |
|
|
2023
Q4 | $3.81M | Sell |
16,115
-4,670
| -22% | -$1.1M | 0.79% | 42 |
|
|
2023
Q3 | $4.07M | Buy |
20,785
+375
| +2% | +$73.5K | 0.92% | 38 |
|
|
2023
Q2 | $4.29M | Buy |
20,410
+1,925
| +10% | +$405K | 0.99% | 37 |
|
|
2023
Q1 | $3.73M | Buy |
18,485
+475
| +3% | +$95.9K | 0.88% | 41 |
|
|
2022
Q4 | $3.92M | Sell |
18,010
-6,210
| -26% | -$1.35M | 0.95% | 39 |
|
|
2022
Q3 | $4.77M | Buy |
24,220
+9,500
| +65% | +$1.87M | 1.33% | 25 |
|
|
2022
Q2 | $3.15M | Buy |
14,720
+590
| +4% | +$126K | 0.85% | 40 |
|
|
2022
Q1 | $4.01M | Buy |
14,130
+10,135
| +254% | +$2.88M | 0.92% | 35 |
|
|
2021
Q4 | $1.51M | Buy |
+3,995
| New | +$1.51M | 0.33% | 66 |
|